AA
WVE icon

AlphaCentric Advisors’s Wave Life Sciences WVE Stock Holding History

AlphaCentric Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
35,670
+6,495
+22% +$43.1K 0.18% 157
2026
Q1 		$212K Buy
29,175
+1,585
+6% +$20.6K 0.21% 140
2025
Q4 		$469K Buy
+27,590
New +$280K 0.47% 67

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

AlphaCentric Advisors's WVE Position: Q2 2026 in Review

AlphaCentric Advisors increased its Wave Life Sciences (WVE) stake by 22% in Q2 2026, buying an estimated $43.1K and bringing the position to 35,670 shares worth $207K. The position accounts for 0.18% of the portfolio, ranked #157.

AlphaCentric Advisors first reported a position in WVE in Q4 2025 and has held it in 3 quarters since. The position peaked at $469K in Q4 2025. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • AlphaCentric Advisors held 35,670 shares of Wave Life Sciences worth $207K as of Q2 2026.
  • AlphaCentric Advisors bought 6,495 Wave Life Sciences shares in Q2 2026, an estimated $43.1K.
  • Wave Life Sciences made up 0.18% of AlphaCentric Advisors's portfolio in Q2 2026, its #157 holding.
  • AlphaCentric Advisors first reported a position in Wave Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Wave Life Sciences position peaked at $469K in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.